Successful conversion surgery after comprehensive therapy in a patient with MSI-H but pMMR metastatic gastric mixed adenoneuroendocrine carcinoma: a case report and literature review

Successful conversion surgery after comprehensive therapy in a patient with MSI-H but pMMR metastatic gastric mixed adenoneuroendocrine carcinoma: a case report and literature review

Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a rare and highly aggressive malignancy characterized by both exocrine and neuroendocrine components. Treatment options for metastatic cases are limited, with typical therapeutic approaches involving a combination of chemotherapy and immunothera...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jun He, Li Wang, Chuanlei Tuo, Weihua Gong, Yong Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Oncology
Subjects:	gastric mixed adenoneuroendocrine carcinoma conversion surgery targeted therapy immunotherapy chemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1463884/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dual-positive gastric cancer: an extremely malignant subtype of gastric cancer with high serum alpha-fetoprotein and carcinoembryonic antigen concentrations
by: Weixun Xie, et al.
Published: (2025-01-01)

Negative response to immunotherapy in dMMR or MSI-H gastric cancer with APC and PTEN mutations: a case report
by: Jiang Liu, et al.
Published: (2024-11-01)

Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer
by: M. V. Sedova, et al.
Published: (2023-06-01)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
by: Akihito Kawazoe, et al.
Published: (2022-02-01)

Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report
by: Sevindzh F. Evdokimova, et al.
Published: (2024-12-01)

Complete response of a metastatic microsatellite-stable gastric cancer after neoadjuvant chemoimmunotherapy: should we still operate? A case report and review of the literature
by: Hiba Mechahougui, et al.
Published: (2024-11-01)

Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
by: Zakari Shaibu, et al.
Published: (2024-10-01)

Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer
by: Keying Che, et al.
Published: (2020-10-01)

Concordance between immunohistochemistry and MSI analysis for detection of MMR/MSI status in colorectal cancer patients
by: Muhammad Ishaque Faizee, et al.
Published: (2024-11-01)

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
by: Dong Luo, et al.
Published: (2025-02-01)

Presentation and outcome of Gastric Cancer at a Tertiary Care Center
by: Sushil Bahadur Rawal, et al.
Published: (2024-11-01)

Practical management of oligometastatic gastric cancer
by: Y. Narita, et al.
Published: (2024-12-01)

Hemophagocytic syndrome secondary to chemotherapy for advanced gastric cancer: A case report
by: Fei-Fei Wang, et al.
Published: (2025-01-01)

Concept of a UTM MMR Training Conversion Kit for the MSBS-5.56 Assault Rifle
by: Przemysław BADUROWICZ, et al.
Published: (2017-09-01)

Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
by: Feng Bi, et al.
Published: (2024-11-01)

C3+ cancer-associated fibroblasts promote tumor growth and therapeutic resistance in gastric cancer via activation of the NF-κB signaling pathway
by: Zhenxiong Zhao, et al.
Published: (2024-12-01)

Optimal hyperthermic intraperitoneal chemotherapy regimen for advanced and peritoneal metastatic gastric cancer: a systematic review and Bayesian network meta-analysis
by: Tianqi Wang, et al.
Published: (2024-11-01)

A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
by: FENG Huizhi, LIU Jingmei, BU Xiaoqian
Published: (2024-11-01)

Tissue Biomarkers in Gastric Cancer Treatment: Present and Future
by: Giulia Airò, et al.
Published: (2024-11-01)

Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy
by: Jiao-Bao Huang, et al.
Published: (2025-01-01)

Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on cholesterol metabolism in gastric cancer
by: Chengjun Zhu, et al.
Published: (2024-12-01)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-01-01)

Prognostic factors and adjuvant chemotherapy efficacy in stage I gastric cancer patients: a retrospective analysis
by: Hua Xiao, et al.
Published: (2024-12-01)

Multiple programmed cell death patterns predict the prognosis and drug sensitivity in gastric cancer
by: Qiying Song, et al.
Published: (2025-02-01)

Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer
by: Yupeng Jiang, et al.
Published: (2025-02-01)

Peripheral T Lymphocyte Predicts the Prognosis of Gastric Cancer Patients Undergoing Radical Gastrectomy: A Multicenter Retrospective Cohort Study
by: Xiao H, et al.
Published: (2024-12-01)

Hypoxia signature derived from tumor-associated endothelial cells predict prognosis in gastric cancer
by: Ruiheng Wang, et al.
Published: (2025-01-01)

Unveiling promising targets in gastric cancer therapy: A comprehensive review
by: Wenke Li, et al.
Published: (2024-09-01)

Immunotherapy for gastric cancer: Advances and challenges
by: Pei Zhang, et al.
Published: (2024-12-01)

Safety assessment of preventive pressurized intraperitoneal aerosol chemotherapy in combined treatment of gastric cancer: preliminary results
by: N. Ya. Muratova, et al.
Published: (2024-03-01)

A Golgi apparatus‑related subtype and risk signature predicts prognosis and evaluates immunotherapy response in gastric cancer
by: Ruyue Chen, et al.
Published: (2025-01-01)

Helicobacter pylori and the microbiome in gastric cancer development and treatment: A year in review
by: P. Vieira, et al.
Published: (2024-09-01)

Photothermally responsive theranostic nanocomposites for near‐infrared light triggered drug release and enhanced synergism of photothermo‐chemotherapy for gastric cancer
by: Taicheng Zhou, et al.
Published: (2023-01-01)

IL-17A in gastric carcinogenesis: good or bad?
by: Weidong Li, et al.
Published: (2024-11-01)

Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer
by: Weiyi Chen, et al.
Published: (2025-01-01)

Methylation of drug resistance‐related genes in chemotherapy‐sensitive Epstein–Barr virus‐associated gastric cancer
by: Hirofumi Ohmura, et al.
Published: (2020-01-01)

Emergency Quick Releasing Mechanism with Spring Linkage and Performance Analysis of the Vehicle Door Latch
by: Zhang Jiale, et al.
Published: (2024-01-01)

ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation
by: Jiaxing Zhang, et al.
Published: (2025-02-01)

Identification of fatty acid anabolism patterns to predict prognosis and immunotherapy response in gastric cancer
by: Weijie Sun, et al.
Published: (2025-01-01)

Harnessing Machine Learning and Nomogram Models to Aid in Predicting Progression-Free Survival for Gastric Cancer Patients Post-Gastrectomy with Deficient Mismatch Repair(dMMR)
by: Yifan Li, et al.
Published: (2025-01-01)